政企联动 凝聚共治合力 创建行动不仅是一系列标准与评选，更成为激发市场内生动力、优化消费环境建设的实践课堂。通过精 准滴灌与正向激励，企业从"要我做"转向"我要做"，政府部门从监管者，拓展为服务者与见证者，最终 汇聚成优化营商环境的合力。 中国质量新闻网讯 2025年，北京市房山区市场监管局、区消费者协会持续优化消费环境建设，培育了 一批在诚信建设方面表现突出的经营主体，1413家商户及7处商业综合体脱颖而出，"诚信经营 放心消 费"创建行动的扎实成果为消费市场注入诚信暖流。 精准施策 夯实诚信根基 自2024年启动"诚信经营 放心消费"创建行动以来，区市场监管局以规范市场秩序、保障消费者合法权 益为核心，多措并举引导企业诚信经营，持续优化区域市场秩序。 行业全覆盖：深耕食品生产经营、餐饮服务、百货零售、药品经营等重点业态，以创建行动为统领，培 育食品生产"优企优品"企业、农村食品经营规范店等优质企业，全域创建氛围愈发浓厚。 标准多维度：从食品生产企业的源头品质把控，到餐饮服务单位的明厨亮灶公示；从集贸市场的"诚信 计量"倡议，到百货门店的"明码标价"承诺。每一家"放心商户"都要经过严格审核，将诚信要求融入采 ...

特朗普23日在社交媒体上宣称，他拥有"充足的其他选项"对进口商品征收关税。 增添不确定性 美国最高法院20日公布裁决后，美国国土安全部下属海关与边境保护局日前证实，将从当地时间24日起 停止收取依据《国际紧急经济权力法》征收的进口商品关税。不过，最高法院裁决只针对特朗普政府征 收的部分关税，其援引第232条款和第301条款等法律条款针对钢铝、家具、铜、汽车等产品加征的关税 依然有效。 美国联邦最高法院日前裁定，美国总统特朗普领导的政府依据《国际紧急经济权力法》所征大规模关税 违法。多家美国媒体23日援引知情人士的话披露，特朗普政府正准备援引关联国家安全的其他法律条款 对6类行业产品加征关税，这部分关税与政府在最高法院裁决后新推出的15%关税不同。 媒体认为，预计特朗普政府新的关税举措将给经济带来更多不确定性。 找理由加税 《纽约时报》等媒体援引知情人士的话披露，美国商务部正着手依据《1962年贸易扩展法》第232条款 对大型电池、铸铁和铁配件、塑料管道、工业化学品以及电网和电信设备等行业产品启动新调查 （即"232调查"）。该条款允许美国政府基于所谓"国家安全风险"征收关税。《华尔街日报》称，暂不 清楚美国商 ...

转自：贵州日报 美国联邦最高法院日前裁定，美国总统特朗普领导的政府依据《国际紧急经济权力法》所征大规模关税 违法。多家美国媒体23日援引知情人士的话披露，特朗普政府正准备援引关联国家安全的其他法律条款 对6类行业产品加征关税，这部分关税与政府在最高法院裁决后新推出的15%关税不同。 媒体认为，预计特朗普政府新的关税举措将给经济带来更多不确定性。 该报还认为，过去一年，特朗普政府已推出了一系列"无法预测的贸易政策"，而新的关税举措又将给经 济带来更多不确定性。曾在民主党籍前总统拜登执政时期出任贸易官员的美国律师格蕾塔·派施说："今 后1个月、2个月或6个月的关税会是什么样，我们比上周更不确定。复杂性和不确定性正在增加。" 新华社电 据《华尔街日报》报道，特朗普政府先前已援引第232条款对半导体、药品、无人机、工业机器人和太 阳能电池板多晶硅等9类行业产品展开调查，不少调查已开展近一年，相关工作可能在最高法院裁决后 加速推进。特朗普政府还有意修改以"国家安全"为由加征的钢铝关税的算法，可能会调低不少产品的名 义关税税率，但同时会依据产品的全部价值而非其钢铝成分的价值来计税。这意味着不少公司最终可能 要多缴关税。 ...

美媒：特朗普政府正酝酿征收新关税 海洋 《纽约时报》等媒体援引知情人士的话披露，美国商务部正着手依据《1962年贸易扩展法》第232条款 对大型电池、铸铁和铁配件、塑料管道、工业化学品以及电网和电信设备等行业产品启动新调查 （即"232调查"）。该条款允许美国政府基于所谓"国家安全风险"征收关税。《华尔街日报》称，暂不 清楚美国商务部何时正式宣布调查，以及相关关税何时正式征收。 美国贸易代表办公室也在着手依据《1974年贸易法》第301条款启动新的贸易调查（即"301调查"），后 续同样可能出台关税措施。该条款允许美国政府对所谓"不公平贸易行为"征收关税。美国贸易代表贾米 森·格里尔20日在声明中说，调查将涉及药品定价、"对美国技术企业及数字产品和服务的歧视"、数字 服务税、与海鲜和大米等产品有关的贸易措施。 据《华尔街日报》报道，特朗普政府先前已援引第232条款对半导体、药品、无人机、工业机器人和太 阳能电池板多晶硅等9类行业产品展开调查，不少调查已开展近一年，相关工作可能在最高法院裁决后 加速推进。特朗普政府还有意修改以"国家安全"为由加征的钢铝关税的算法，可能会调低不少产品的名 义关税税率，但同时会依据 ...

健康消费市场之所以出现这样的乱象，原因是多方面的。首先，是老年人的健康焦虑日益凸显。随着年龄增长，老年人的身体机能逐渐下降，对健康的渴望 越来越强烈，容易被"治百病""延年益寿"等虚假宣传迷惑，从而盲目消费。其次，是信息不对称。老年人对药品知识和养生常识了解有限，无法辨别产品宣 传的真假，容易被骗子忽悠。 此外，部分企业的违规操作，也加剧了市场的混乱。一些企业为了追求高额利润，不惜篡改产品名称、夸大疗效，通过直播、短视频、线下讲座等方式，虚 假宣传产品功效，诱导老年人消费。还有一些企业，利用老年人对"古方""秘方"的信任，编造虚假的产品渊源，给普通药品贴上"古方"标签，抬高产品价 格。 72岁老人唐女士花16800元购买的"神仙不老丸"，拆开包装后竟是市面上常见的康欣口服液——这款售价仅几百元的正规中成药，被骗子通过虚假宣传，炒 作成"能治百病、延年益寿"的天价"神药"，最终导致唐女士胃疼住院。记者调查发现，这种将正规药品炒作成"神药"的现象，在老年健康消费市场中并不少 见，背后折射出的，是整个健康消费市场的混乱与无序。 据了解，康欣口服液是一款经过国家药品监督管理局批准的正规中成药，其主要成分包括丹参、当归 ...

参考消息网2月22日报道 据法新社2月21日报道，美国最高法院周五(20日)裁定，唐纳德·特朗普自重返 白宫以来实施的大部分关税均属非法，这使他经济计划的一个重要支柱被推翻。 但美国总统当晚宣布签署一项行政令，将从2月24日起征收10%的全球性新关税，为期150天。 另一个后果是，已支付这些关税的企业可以申请退税。一些企业此前已预判到裁决结果，提起了相关诉 讼。 然而，确切金额难以确定，经济学家估计2025年所谓的"对等"关税带来的财政收入约为1300亿或1400亿 美元。 特朗普在1月中旬曾刻意夸大后果，称若最高法院作出不利裁决，将需退还"数千亿美元"。 周五他更为直接地表示，这个问题将在法庭上解决。伊利诺伊州民主党州长已根据耶鲁大学的估算，要 求每户家庭获得1700美元的退税。而加利福尼亚州州长则认为，政府应该向消费者进行补偿。 法新社对这一裁决的影响进行了盘点。 预计会有退税 最高法院的裁决事实上取消了所谓的"对等"关税，这些关税此前适用于几乎所有进入美国的产品。 但该裁决不涉及针对某些行业征收的关税，如汽车、钢铁、铝材或药品。 安永-博智隆公司首席经济学家格雷戈里·达科指出，直接后果将是进口产品实际平 ...

Core Viewpoint - Mogao Co., Ltd. (600543) is facing potential delisting risk due to expected losses and revenue shortfalls, leading to a significant decline in stock price [1][2] Recent Events - The company announced on January 30, 2026, that it expects a net profit for 2025 to be between -100 million to -120 million yuan, with operating revenue excluding specific income below 300 million yuan [2] - The potential delisting risk warning (ST) is based on the Shanghai Stock Exchange's listing rules and will depend on the audited results of the 2025 annual report [2] Performance and Operations - The company plans to disclose the 2025 annual report by the end of April 2026, which will confirm the extent of losses and revenue details [3] - The decline in performance is primarily attributed to a deep adjustment in the wine industry, decreased demand for cough medicine, and pressure on the biodegradable materials business [3] Stock Performance - On February 2, 2026, the company's stock hit the daily limit down due to concerns over expected losses and delisting risks, with a drop of 5.67% [4] - Market confidence has been affected by performance expectations, as evidenced by a 2.01% decline in stock price on February 12, 2026 [4] Company Situation - The controlling shareholder, Gansu Agricultural Reclamation Group, has previously increased its stake and established a capital operation team to promote mergers and restructuring to improve operations [5] - The restructuring attempt in 2024 was terminated, and the feasibility of a new plan in 2025 remains to be seen [5] Industry Policy and Environment - The wine, pharmaceutical, and biodegradable materials sectors are facing intensified competition and regulatory pressures, which may continue to impact the company's performance in 2026 [6]

Core Viewpoint - The article emphasizes the importance of ensuring the safety of pharmaceuticals and medical devices during the winter season through a regulatory initiative in Xinjiang Shawan City, aimed at protecting public health [1] Group 1: Regulatory Actions - The Xinjiang Shawan City Market Supervision Administration is conducting a "100-day rectification action" focused on the quality and safety of pharmaceuticals and medical devices during winter [1] - The initiative targets pharmaceutical and medical device businesses, verifying the validity of operating licenses, legality of procurement channels, compliance in storage and maintenance, and completeness of incoming inspection [1] Group 2: Focus Areas - Key areas of focus include cold-chain pharmaceuticals, traditional Chinese medicine pieces, and commonly used medical devices [1] - The enforcement personnel are combining law enforcement with service, providing on-site guidance for businesses to standardize management and assisting with license changes [1] Group 3: Future Plans - The Xinjiang Shawan City Market Supervision Administration plans to continue enhancing precise regulation and warm service to further advance the "100-day rectification action" for pharmaceutical and medical device quality and safety [1] - The initiative aims to reinforce the primary responsibility of enterprises, ensuring that the public can use medications and medical devices with greater confidence during the winter [1]

Core Insights - The Beijing Municipal Market Supervision Work Conference emphasized the focus on addressing monopolistic behaviors in public utilities and platform economies, as well as tackling unfair competition in the digital space [1] Group 1: Business Environment and Growth - As of the end of 2025, the total number of business entities in Beijing reached 2.8697 million, marking a year-on-year growth of 6.83%, with over 40% being technology-based enterprises [2] - The survival rate of businesses over the past three years has remained above 75%, with the quality of business development ranking first in the nation for three consecutive years [2] - A series of reforms have been implemented, including the introduction of local standards for registration services and a new model for equity trust property registration [2] Group 2: Regulatory Innovations - The year 2026 will focus on deepening reform and enhancing regulatory efficiency, including the promotion of standardized address registration and the expansion of electronic business licenses [3] - The introduction of "code checks" will be expanded, with a strong push for "bright code checks" to improve regulatory effectiveness [3] - The regulatory framework will also include collaborative enforcement across industries to address monopolistic practices and unfair competition [3] Group 3: Consumer Protection and Safety - Plans are in place to establish 100 consumer rights protection service stations and enhance the functionality of electronic scales to prevent fraud [4] - The construction of a food safety traceability and risk warning system will be accelerated, alongside the implementation of "Internet + AI regulation" [4] - Continuous governance of key products such as electric bicycles and gas appliances will be prioritized, with a focus on enhancing drug safety and regulatory standards [4]

Core Insights - The article discusses the performance of actively managed equity funds established in 2021, revealing that over 50% of these funds are currently at a loss, with significant declines in value for many [1] Fund Performance Summary - A total of 667 actively managed equity funds established in 2021 were analyzed, with approximately 362 funds showing negative returns since inception, representing over 54% of the sample [1] - Among these, 86 funds have experienced declines of over 30%, and 34 funds have seen declines exceeding 40% [1] - The "Oriental Quality Consumption One-Year Holding Period Mixed Fund," established in July 2021, has recorded a cumulative decline of approximately 60.6%, making it one of the worst performers in the sample [1][3] Specific Fund Data - The "Oriental Quality Consumption One-Year Holding Period Mixed Fund A" has a current net value of 0.4015, with a cumulative return of -59.85% since its inception [2] - The fund's performance over the past year shows a decline of -1.45%, and over three years, it has decreased by -34.56% [2] - The fund's top ten holdings include major companies such as Yili Group, Midea Group, and Tencent Holdings, but it has consistently underperformed compared to its peers and the CSI 300 index [3][4] Comparative Performance Analysis - In 2025, the fund's annual return was -0.53%, while the average return for similar funds was 33.12%, and the CSI 300 index returned 17.66% [4] - The fund's ranking among peers has been poor, with significant drops in its position over the years, indicating a consistent underperformance [4][6]